Pentraxin Therapeutics Ltd is a University College London spin out company founded in 2001 by Professor Sir Mark Pepys FRS. In September 2011 Sir Mark retired as head of medicine at the Royal Free Campus of UCL and became the first Director of the new UCL Wolfson Drug Discovery Unit, which was created with funding from the Wolfson Foundation. Pentraxin holds the intellectual property and proprietary knowledge created by Sir Mark’s research group. The company designs new treatments for systemic amyloidosis and the amyloid-related diseases, Alzheimer’s disease and type II diabetes, as well as targeting the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases. Development of these inventions is proceeding both within the UCL environment, supported by the Medical Research Council and the UCL/UCLH Biomedical Research Centre, and through extensive collaborations with GlaxoSmithKline, one of the world’s leading pharmaceutical companies.
You can find details of Pentraxin’s current R&D Programmes by clicking on the “R&D Programmes” tab above. The “News” tab will take you to the latest updates on Pentraxin’s research and collaborations and “Links” contains links to related sites.